Ligand Pharmaceuticals (LGND) Price Target Increased to $280.00 by Analysts at HC Wainwright

Author: Joseph McCarthy

Published: Oct. 19, 2018, 9:30 a.m. ==> 3 months ago



Ligand Pharmaceuticals (NASDAQ:LGND) had its price objective upped by equities research analysts at HC Wainwright from $270.00 to $280.00 in a report issued on Tuesday, October 2nd, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 42.09% from the […]

More Info